Biomea Fusion (Nasdaq:BMEA) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

BMEA Aktienübersicht

BMEA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 73.56%

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Volatiler Aktienkurs in den letzten 3 Monaten

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Biomea Fusion, Inc. Wettbewerber

Fate Therapeutics

NasdaqGM:FATE

US$400.7m

LENZ Therapeutics

NasdaqGS:LENZ

US$400.9m

Adlai Nortye

NasdaqGM:ANL

US$387.5m

Cibus

NasdaqCM:CBUS

US$383.6m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Biomea Fusion
Historical stock prices
Current Share Price	US$11.65
52 Week High	US$43.69
52 Week Low	US$8.13
Beta	-0.35
1 Month Change	8.07%
3 Month Change	-37.06%
1 Year Change	-65.59%
3 Year Change	-37.83%
5 Year Change	n/a
Change since IPO	-37.37%

Aktuelle Nachrichten und Updates

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Feb 22

Recent updates

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

Aug 01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Jul 20

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Mar 16

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Nov 27

Biomea Fusion: Patience Warranted

Sep 23

Aktionärsrenditen

	BMEA	US Biotechs	US Markt
7D	0.6%	-2.9%	-0.6%
1Y	-65.6%	6.6%	25.4%

Rendite im Vergleich zur Industrie: BMEA unter dem Niveau der Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4% erzielte.

Rendite vs. Markt: BMEA hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is BMEA's price volatile compared to industry and market?
BMEA volatility
BMEA Average Weekly Movement	11.8%
Biotechs Industry Average Movement	11.0%
Market Average Movement	5.9%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: BMEADer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: BMEADie wöchentliche Volatilität (12%) war im letzten Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2017	110	Thomas Butler	biomeafusion.com

Biomea Fusion, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung und Entwicklung von kovalenten niedermolekularen Medikamenten zur Behandlung von Patienten mit genetisch bedingten Krebserkrankungen und Stoffwechselkrankheiten konzentriert. Sein führender Produktkandidat ist BMF-219, ein kovalenter Inhibitor von Menin zur Behandlung von Patienten mit flüssigen und festen Tumoren und Typ-2-Diabetes. Das Unternehmen wurde im Jahr 2017 gegründet und hat seinen Hauptsitz in Redwood City, Kalifornien.

Biomea Fusion, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Biomea Fusion im Vergleich zum Marktanteil des Unternehmens?
BMEA grundlegende Statistiken
Marktanteil	US$395.39m
Gewinn(TTM)	-US$127.26m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-3.3x

Kurs-Gewinn-Verhältnis

Ist BMEA zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BMEA Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$127.27m
Umsatz	-US$127.26m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-3.54
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich BMEA auf lange Sicht entwickelt?

Historische Performance und Vergleiche

BMEA Aktienübersicht

Belohnungen

Risikoanalyse

Biomea Fusion, Inc. Wettbewerber

NasdaqGM:FATE

US$400.7m

NasdaqGS:LENZ

US$400.9m

NasdaqGM:ANL

US$387.5m

NasdaqCM:CBUS

US$383.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Recent updates

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target increased by 17% to US$48.63

Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific Sessions

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Price target increased by 24% to US$27.50

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

High number of new and inexperienced directors

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Price target increased to US$23.60

Biomea Fusion, Inc. Announces First Patient Dosed with Chronic Lymphocytic Leukemia (Cll) in Covalent-101 Trial

FDA Clears Biomea's IND Application to Begin A Phase I/Ib Trial of BMF-219

Biomea Fusion Presents New Preclinical Data At the European Association for the Study of Diabetes (Easd) Annual Meeting Describing Bmf-219’S Potential as A Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Growth Index

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc. Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models At Ada 2022

Price target decreased to US$19.50

Biomea Fusion, Inc. Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$21.00

High number of new and inexperienced directors

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

High number of new and inexperienced directors

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Biomea Plans to Initiate Enrollment of Patients with MM and Diffuse Large B-Cell Lymphoma (DLBCL) in the Ongoing Phase I Clinical Trial of BMF-219 in the First Half of 2022

Biomea Fusion, Inc. Appoints Steve Morris, M.D. as Chief Medical Officer

Biomea Fusion, Inc. Announces First Patient Dosed

CFO & Principal Accounting Officer recently bought US$87k worth of stock

Biomea Fusion, Inc. Announces 2022 Clinical Development Plan to Initiate Studies in Up to Seven Different Tumor Types and in Diabetes for BMF-219

Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

High number of new directors

Erträge & Einnahmen